184 related articles for article (PubMed ID: 21515045)
21. 5alpha-Reductase inhibitor treatment of prostatic diseases: background and practical implications.
Dörsam J; Altwein J
Prostate Cancer Prostatic Dis; 2009; 12(2):130-6. PubMed ID: 19030020
[TBL] [Abstract][Full Text] [Related]
22. Uvaria rufa Blume attenuates benign prostatic hyperplasia via inhibiting 5α-reductase and enhancing antioxidant status.
Buncharoen W; Saenphet K; Saenphet S; Thitaram C
J Ethnopharmacol; 2016 Dec; 194():483-494. PubMed ID: 27732901
[TBL] [Abstract][Full Text] [Related]
23. Design, synthesis and biological evaluation of novel 3-oxo-4-oxa-5α-androst-17β-amide derivatives as dual 5α-reductase inhibitors and androgen receptor antagonists.
Lao K; Sun J; Wang C; Wang Y; You Q; Xiao H; Xiang H
Bioorg Med Chem Lett; 2017 Sep; 27(17):4212-4217. PubMed ID: 28757062
[TBL] [Abstract][Full Text] [Related]
24. Doping-control analysis of the 5alpha-reductase inhibitor finasteride: determination of its influence on urinary steroid profiles and detection of its major urinary metabolite.
Thevis M; Geyer H; Mareck U; Flenker U; Schänzer W
Ther Drug Monit; 2007 Apr; 29(2):236-47. PubMed ID: 17417080
[TBL] [Abstract][Full Text] [Related]
25. Comparative study of human steroid 5alpha-reductase isoforms in prostate and female breast skin tissues: sensitivity to inhibition by finasteride and epristeride.
Ranjan M; Diffley P; Stephen G; Price D; Walton TJ; Newton RP
Life Sci; 2002 May; 71(2):115-26. PubMed ID: 12031682
[TBL] [Abstract][Full Text] [Related]
26. Inhibition of androgen induces autophagy in benign prostate epithelial cells.
Li M; Yang X; Wang H; Xu E; Xi Z
Int J Urol; 2014 Feb; 21(2):195-9. PubMed ID: 23819759
[TBL] [Abstract][Full Text] [Related]
27. The effect of finasteride in men with benign prostatic hyperplasia. The Finasteride Study Group.
Gormley GJ; Stoner E; Bruskewitz RC; Imperato-McGinley J; Walsh PC; McConnell JD; Andriole GL; Geller J; Bracken BR; Tenover JS
N Engl J Med; 1992 Oct; 327(17):1185-91. PubMed ID: 1383816
[TBL] [Abstract][Full Text] [Related]
28. Finasteride treatment alters tissue specific androgen receptor expression in prostate tissues.
Bauman TM; Sehgal PD; Johnson KA; Pier T; Bruskewitz RC; Ricke WA; Huang W
Prostate; 2014 Jun; 74(9):923-32. PubMed ID: 24789081
[TBL] [Abstract][Full Text] [Related]
29. Comparison of histological compositions and apoptosis in canine spontaneous benign prostatic hyperplasia treated with androgen suppressive agents chlormadinone acetate and finasteride.
Shibata Y; Fukabori Y; Ito K; Suzuki K; Yamanaka H
J Urol; 2001 Jan; 165(1):289-93. PubMed ID: 11125427
[TBL] [Abstract][Full Text] [Related]
30. [Hormonal therapy for benign prostatic hyperplasia].
Sakai H; Kanetake H
Nihon Rinsho; 2002 Dec; 60 Suppl 11():358-61. PubMed ID: 12599600
[No Abstract] [Full Text] [Related]
31. [Effect of selective 5alpha-reductase inhibitor or/and testosterone undecanoate on the reproductive function of male rats].
Jia Y; Cue YG; Wang XD; Wang XH; Tong JS; Ma DZ; Cai RF; Di FS
Zhonghua Nan Ke Xue; 2005 Jan; 11(1):38-41. PubMed ID: 15704680
[TBL] [Abstract][Full Text] [Related]
32. 19-nor-10-azasteroids: a novel class of inhibitors for human steroid 5alpha-reductases 1 and 2.
Guarna A; Belle C; Machetti F; Occhiato EG; Payne AH; Cassiani C; Comerci A; Danza G; De Bellis A; Dini S; Marrucci A; Serio M
J Med Chem; 1997 Mar; 40(7):1112-29. PubMed ID: 9089333
[TBL] [Abstract][Full Text] [Related]
33. [Epididymis in an experimental model of DHT deficiency: immunolocalization of ERalpha and ERbeta in rat epididymal epithelial cells. In vivo and in vitro studies].
Kolasa A
Ann Acad Med Stetin; 2006; 52(2):13-21; discussion 21. PubMed ID: 17633123
[TBL] [Abstract][Full Text] [Related]
34. Inhibitory effects of isoflavonoids on rat prostate testosterone 5α-reductase.
Bae M; Woo M; Kusuma IW; Arung ET; Yang CH; Kim YU
J Acupunct Meridian Stud; 2012 Dec; 5(6):319-22. PubMed ID: 23265084
[TBL] [Abstract][Full Text] [Related]
35. A novel in vitro model to screen steroid 5 alpha-reductase inhibitors against benign prostatic hyperplasia.
Sun ZY; Tu ZH
Methods Find Exp Clin Pharmacol; 1998 May; 20(4):283-7. PubMed ID: 9658376
[TBL] [Abstract][Full Text] [Related]
36. Finasteride treatment and neuroactive steroid formation.
Dusková M; Hill M; Hanus M; Matousková M; Stárka L
Prague Med Rep; 2009; 110(3):222-30. PubMed ID: 19655698
[TBL] [Abstract][Full Text] [Related]
37. Aromatic esters of progesterone as 5alpha-reductase and prostate growth inhibitors.
Bratoeff E; Segura T; Recillas S; Carrizales E; Palacios A; Heuze I; Cabeza M
J Enzyme Inhib Med Chem; 2009 Jun; 24(3):655-62. PubMed ID: 18825535
[TBL] [Abstract][Full Text] [Related]
38. Finasteride-Induced Inhibition of 5α-Reductase Type 2 Could Lead to Kidney Damage-Animal, Experimental Study.
Baig MS; Kolasa-Wołosiuk A; Pilutin A; Safranow K; Baranowska-Bosiacka I; Kabat-Koperska J; Wiszniewska B
Int J Environ Res Public Health; 2019 May; 16(10):. PubMed ID: 31100850
[TBL] [Abstract][Full Text] [Related]
39. Combined effect of the finasteride and doxazosin on rat ventral prostate morphology and physiology.
Justulin LA; Acquaro C; Carvalho RF; Silva MD; Felisbino SL
Int J Androl; 2010 Jun; 33(3):489-99. PubMed ID: 19490185
[TBL] [Abstract][Full Text] [Related]
40. Dutasteride, the dual 5alpha-reductase inhibitor, inhibits androgen action and promotes cell death in the LNCaP prostate cancer cell line.
Lazier CB; Thomas LN; Douglas RC; Vessey JP; Rittmaster RS
Prostate; 2004 Feb; 58(2):130-44. PubMed ID: 14716738
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
